Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab in Relapsed/Refractory Ewing's Sarcoma
NCT00560235Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of figitumumab in Ewing sarcoma, sponsored by Pfizer. Started Mar 2008; status: completed.
02
Drugs
figitumumab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT00560235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560235.